Condition: Atopic Dermatitis · Sponsor: Sanofi
This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients. The study will recruit participants from AD patients who are already receiving dupilumab treatment. The study enrollment period will be about 9 months with each of the participants undergoing a 6-month observational study period.
This description comes directly from the study's public registry record.
Trial Transparency email recommended (Toll free for US & Canada) · 800-633-1610 · Contact-US@sanofi.com
Always discuss trial participation with your own doctor first.
| Investigational Site: Hamad Medical Corporation | Doha, Qatar | Active Not Recruiting |
| Investigational Site: Saudi Medical Services (Medical Fakeeh) | Jeddah, Saudi Arabia | Recruiting |
| Investigational Site: King Faisal Specialist Hospital | Jeddah, Saudi Arabia | Active Not Recruiting |
| Investigational Site: NMC Specialty Hospital LTD | Abu Dhabi, United Arab Emirates | Recruiting |
| Investigational Site: Dibba Hospital | Fujairah, United Arab Emirates | Recruiting |
| Investigational Site: Ibrahem Bin Hamad Hospital | Ras al-Khaimah, United Arab Emirates | Recruiting |
| Investigational Site: Al Qassimi Hospital | Sharjah city, United Arab Emirates | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07467564